Read our latest news!

Posted on June 3, 20216/3/21

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

Posted on May 26, 20215/26/21

EVERSANA™ and S3 Connected Health Announce Strategic Partnership to Advance the Adoption and Commercialization of Digital Health Solutions Across Life Sciences

Posted on May 19, 20215/19/21

MedRhythms and EVERSANA announce partnership to launch and commercialize chronic stroke software-based medical device

EVERSANA
Posted on May 18, 20215/18/21

EVERSANA™ expands global agency and marketing capabilities through partnership with thenetworkone

EVERSANA
Posted on May 14, 20215/14/21

EVERSANA™ Leaders Jim Lang, Brigham Hyde Named to 2021 PM360 Elite 100 List

Posted on May 6, 20215/6/21

EVERSANA advances commercialization readiness as Humanigen announces publication of phase 3 randomized double-blind placebo-controlled study demonstrating the efficacy and safety of lenzilumab™ in newly hospitalized COVID-19 patients

EVERSANA
Posted on May 6, 20215/6/21

EVERSANA™ strengthens global market access and pricing leadership in European expansion

Posted on April 6, 20214/6/21

EVERSANA Commercialization Executive Krista Pinto Named 2021 MM+M Hall of Femme Honoree

Posted on March 23, 20213/23/21

Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi for Mydriasis

EVERSANA
Posted on February 25, 20212/25/21

EVERSANA Launches Chronic Disease Real-World Data Solution Covering More Than 80 Million Deidentified Patients to Drive Regulatory-Grade Clinical Research and Improve Patient Outcomes

Discover EVERSANA

  • Resource Center

    We’re driven by a diverse team of experts who understand the challenges facing today's industry.

    Learn More
  • Experts

    We’re driven by a diverse team of experts who understand the challenges facing today's industry.

    Experts